[go: up one dir, main page]

MX2009004386A - Compuestos inhibidores de proteina de transferencia de trigliceridos microsomales de acido tetrahidro-naftalen-1-carboxil ico sustituidos con piperidina o piperazina. - Google Patents

Compuestos inhibidores de proteina de transferencia de trigliceridos microsomales de acido tetrahidro-naftalen-1-carboxil ico sustituidos con piperidina o piperazina.

Info

Publication number
MX2009004386A
MX2009004386A MX2009004386A MX2009004386A MX2009004386A MX 2009004386 A MX2009004386 A MX 2009004386A MX 2009004386 A MX2009004386 A MX 2009004386A MX 2009004386 A MX2009004386 A MX 2009004386A MX 2009004386 A MX2009004386 A MX 2009004386A
Authority
MX
Mexico
Prior art keywords
naphthalene
piperidine
compounds
substituted tetrahydro
piperazine substituted
Prior art date
Application number
MX2009004386A
Other languages
English (en)
Inventor
Lieven Meerpoel
Joannes Theodorus Maria Linders
Libuse Jaroskova
Marcel Viellevoye
Leo Jacobus Jozef Backx
Didier Jean-Claude Berthelot
Guuske Frederike Busscher
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009004386A publication Critical patent/MX2009004386A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos derivados del ácido tetrahidro-naftalen-1-carboxílico sustituidos con piperidina o piperazina que tienen actividad inhibidora de secreción de apoB/MTP y actividad reductora de lípidos concomitante; además, la invención se refiere a métodos para preparar dichos compuestos, composiciones farmacéuticas que comprenden dichos compuestos, así como también el uso de dichos compuestos como medicamento para tratar aterosclerosis, pancreatitis, obesidad, hipertrigliceridemia, hipercolesterolemia, hiperlipidemia, diabetes y diabetes de tipo II.
MX2009004386A 2006-10-24 2007-10-22 Compuestos inhibidores de proteina de transferencia de trigliceridos microsomales de acido tetrahidro-naftalen-1-carboxil ico sustituidos con piperidina o piperazina. MX2009004386A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06122817 2006-10-24
PCT/EP2007/061286 WO2008049806A1 (en) 2006-10-24 2007-10-22 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds

Publications (1)

Publication Number Publication Date
MX2009004386A true MX2009004386A (es) 2009-05-08

Family

ID=37885794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004386A MX2009004386A (es) 2006-10-24 2007-10-22 Compuestos inhibidores de proteina de transferencia de trigliceridos microsomales de acido tetrahidro-naftalen-1-carboxil ico sustituidos con piperidina o piperazina.

Country Status (27)

Country Link
US (1) US8114880B2 (es)
EP (1) EP2076494B1 (es)
JP (1) JP5506085B2 (es)
KR (1) KR101415536B1 (es)
CN (1) CN101528695B (es)
AR (1) AR063517A1 (es)
AT (1) ATE475648T1 (es)
AU (1) AU2007310925B2 (es)
BR (1) BRPI0717357A2 (es)
CA (1) CA2664141C (es)
CL (1) CL2007003042A1 (es)
CY (1) CY1111010T1 (es)
DE (1) DE602007008124D1 (es)
DK (1) DK2076494T3 (es)
EA (1) EA016311B1 (es)
IL (1) IL198332A (es)
JO (1) JO2653B1 (es)
MX (1) MX2009004386A (es)
NO (1) NO20092005L (es)
NZ (1) NZ575615A (es)
PL (1) PL2076494T3 (es)
PT (1) PT2076494E (es)
SI (1) SI2076494T1 (es)
TW (1) TWI396688B (es)
UA (1) UA99109C2 (es)
WO (1) WO2008049806A1 (es)
ZA (1) ZA200902822B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP2076487B1 (en) * 2006-10-24 2010-05-26 Janssen Pharmaceutica N.V. Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
SMT201700533T1 (it) * 2010-10-18 2018-01-11 Cerenis Therapeutics Holding Sa Composti, composizioni e metodi utili per la mobilitazione del colesterolo
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
DK3484528T3 (da) 2016-07-18 2021-02-15 Janssen Pharmaceutica Nv Tau-pet-billeddannelsesligander
WO2019221192A1 (ja) * 2018-05-15 2019-11-21 旭化成株式会社 アミノ酸アミノアルキルエステル又はその無機酸塩の製造方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
EP3873214A4 (en) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone
WO2024006701A1 (en) * 2022-06-28 2024-01-04 Stepan Company Method for making dialkyl amino acid ester sulfonates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
CA2272719C (en) 1996-11-27 2002-10-01 Pfizer Limited Apo b-secretion/mtp inhibitory amides
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
DE19963235A1 (de) * 1999-12-27 2001-07-05 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
EP2076487B1 (en) 2006-10-24 2010-05-26 Janssen Pharmaceutica N.V. Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives

Also Published As

Publication number Publication date
PL2076494T3 (pl) 2011-01-31
AU2007310925A1 (en) 2008-05-02
TW200833680A (en) 2008-08-16
CY1111010T1 (el) 2015-06-11
CN101528695B (zh) 2013-07-17
KR20090075832A (ko) 2009-07-09
CA2664141A1 (en) 2008-05-02
NZ575615A (en) 2011-01-28
HK1136823A1 (en) 2010-07-09
CA2664141C (en) 2015-04-28
AU2007310925B2 (en) 2012-07-26
CN101528695A (zh) 2009-09-09
DE602007008124D1 (de) 2010-09-09
EA200970398A1 (ru) 2009-08-28
EP2076494B1 (en) 2010-07-28
ZA200902822B (en) 2010-07-28
TWI396688B (zh) 2013-05-21
IL198332A0 (en) 2010-02-17
IL198332A (en) 2012-08-30
SI2076494T1 (sl) 2010-11-30
BRPI0717357A2 (pt) 2013-10-22
EA016311B1 (ru) 2012-04-30
EP2076494A1 (en) 2009-07-08
NO20092005L (no) 2009-06-04
UA99109C2 (ru) 2012-07-25
JP2010507615A (ja) 2010-03-11
US8114880B2 (en) 2012-02-14
AR063517A1 (es) 2009-01-28
JO2653B1 (en) 2012-06-17
WO2008049806A1 (en) 2008-05-02
KR101415536B1 (ko) 2014-07-16
JP5506085B2 (ja) 2014-05-28
ATE475648T1 (de) 2010-08-15
CL2007003042A1 (es) 2008-05-02
DK2076494T3 (da) 2010-11-08
PT2076494E (pt) 2010-10-18
US20090325980A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
MX2009004386A (es) Compuestos inhibidores de proteina de transferencia de trigliceridos microsomales de acido tetrahidro-naftalen-1-carboxil ico sustituidos con piperidina o piperazina.
JO2537B1 (en) Aryl-pyridine or pyrezinate compounds replaced with heterogeneous pentagonal rings used as inhibitors of MTB proteins
MX2010002461A (es) (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento.
MX2011012017A (es) Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl).
BRPI0613754B8 (pt) compostos, éster de um composto, composições farmacêuticas que compreendem o composto, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por análogos de hormônio de tireóide e utilização dos compostos
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
MX2011012122A (es) Derivados de tiofeno.
MX2010008051A (es) Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos.
IL192847A (en) The history of benzamide and the trower, a process for making them and their pharmaceutical preparations
IN2012DN02502A (es)
MY148406A (en) 4-[(3-fluorophenoxy)phenylmethyl] piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
BR0313377A (pt) Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b
EA200970170A1 (ru) Производные 4-триметиламмоний-3-аминобутирата и 4-триметилфосфоний-3-аминобутирата как ингибиторы срт
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
IL198333A0 (en) Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives
EA200601120A1 (ru) N-арилпиперидинзамещённые бифинилкарбоксамиды в качестве ингибиторов аполипопротеина в
UA87284C2 (ru) Соединения фенилпиридилпиперазина, способ их получения и фармацевтическая композиция, которая их содержит
DE602007010725D1 (de) Verfahren und zwischenprodukt zur herstellung von donezepil
NZ589911A (en) Styrylbenzofuran derivatives as inhibitors for beta-amyloid fibril formation and preparation method thereof
EA201101175A1 (ru) Фармацевтические комбинации 5-фторурацила и производных 1,4-дигидропиридина и их применение для лечения рака
NO20064601L (no) Mtp-hemmende aryl-piperidiner eller -piperaziner substituert med 5-leddede heterocykler
SI1546083T1 (sl) Nove substituirane arilheksadienojske kisline in njihovi estri ki se lahko uporabljajo za zdravljenje in preprečevanje diabetesa dislipidemije in ateroskleroze farmacevtski sestavki ki jih vsebujejo in postopek njihove priprave

Legal Events

Date Code Title Description
FG Grant or registration